PMID- 15581965
OWN - NLM
STAT- MEDLINE
DCOM- 20050125
LR  - 20141120
IS  - 0090-8258 (Print)
IS  - 0090-8258 (Linking)
VI  - 95
IP  - 3
DP  - 2004 Dec
TI  - Her-2/neu expression and amplification in early stage ovarian surface epithelial 
      neoplasms.
PG  - 570-5
AB  - OBJECTIVE: The aim of this study is to examine Her-2/neu gene amplification and 
      protein overexpression in a spectrum of ovarian neoplasms using both 
      immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) 
      techniques that are FDA approved. This study is focused on early stage tumors 
      including both carcinomas and borderline tumors. METHODS: FDA-approved IHC and 
      FISH for Her-2/neu were performed on formalin-fixed, paraffin-embedded tissue 
      from 79 ovarian neoplasms representing a broad spectrum of tumor types as well as 
      four normal ovaries. All tumors were either stage I or stage II. Tumor and normal 
      tissue were studied collectively using a tissue microarray (TMA). HercepTest 
      (DAKO) and PathVysion Her-2/neu probe kit (Vysis Inc.) were used for IHC and FISH 
      analysis. RESULTS: FISH analysis of serous carcinomas demonstrated Her-2/neu gene 
      amplification in 3 (18%) of 17 cases. Two of three cases showing Her-2/neu gene 
      amplification were scored 1+ using IHC, while the remaining case was scored as 0. 
      Analysis of endometrioid carcinomas demonstrated Her-2/neu amplification using 
      FISH in 1 of 10 (10%) cases. IHC in this case was scored 2+ (positive). None of 
      the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional 
      cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not 
      otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; 
      endometrioid, n = 7; serous, n = 7), showed Her-2/neu gene amplification or 
      protein overexpression. Normal ovaries were negative as well. CONCLUSIONS: 
      Amplification of Her-2/neu in early stage ovarian neoplasms is infrequent, 6.7% 
      overall. Due to the limited number of informative cases, we were unable to 
      determine the clinical significance of Her-2/neu amplification in this study. 
      Her-2/neu amplification was restricted to carcinomas and was not encountered in 
      ovarian borderline tumors.
FAU - Wu, Yun
AU  - Wu Y
AD  - Department of Pathology, Division of Gynecology, Memorial Sloan-Kettering Cancer 
      Center, 1275 York Avenue, New York, NY 10021, USA.
FAU - Soslow, Robert A
AU  - Soslow RA
FAU - Marshall, David S
AU  - Marshall DS
FAU - Leitao, Mario
AU  - Leitao M
FAU - Chen, Beiyun
AU  - Chen B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Endometrioid/genetics/metabolism/pathology
MH  - Cystadenocarcinoma, Serous/genetics/metabolism/pathology
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/genetics/*metabolism/pathology
MH  - Receptor, ErbB-2/*biosynthesis/genetics
EDAT- 2004/12/08 09:00
MHDA- 2005/01/26 09:00
CRDT- 2004/12/08 09:00
PHST- 2004/04/13 00:00 [received]
PHST- 2004/12/08 09:00 [pubmed]
PHST- 2005/01/26 09:00 [medline]
PHST- 2004/12/08 09:00 [entrez]
AID - S0090-8258(04)00649-3 [pii]
AID - 10.1016/j.ygyno.2004.08.043 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2004 Dec;95(3):570-5. doi: 10.1016/j.ygyno.2004.08.043.